Citations (71)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Rajani Kanteti, Immanuel Dhanasingh, Essam El-Hashani, Jacob J. Riehm, Thomas Stricker, Stanislav Nagy, Alexander Zaborin, Olga Zaborina, David Biron, John C. Alverdy, Hae Kyung Im, Shahid Siddiqui, Pamela A. Padilla & Ravi Salgia. (2016) C. elegans and mutants with chronic nicotine exposure as a novel model of cancer phenotype. Cancer Biology & Therapy 17:1, pages 91-103.
Read now
Read now
Articles from other publishers (70)
Francisca Diniz, Sofia Lamas, Hugo Osório, Paulo Aguiar, Daniela Freitas, Fátima Gartner, Bruno Sarmento, Celso A. Reis & Joana Gomes. (2023) Nanoparticles targeting Sialyl-Tn for efficient tyrosine kinase inhibitor delivery in gastric cancer. Acta Biomaterialia.
Crossref
Crossref
C. Röcken. (2022) Predictive biomarkers in gastric cancer. Journal of Cancer Research and Clinical Oncology 149:1, pages 467-481.
Crossref
Crossref
Kewei Song, Baohong Gu, Chenhui Ma, Bofang Wang, Na Wang, Rong Yu & Hao Chen. (2022) Epithelial-Mesenchymal Transition Gene Signature Is Associated with Neoadjuvant Chemoradiotherapy Resistance and Prognosis of Esophageal Squamous Cell Carcinoma. Disease Markers 2022, pages 1-14.
Crossref
Crossref
Xin-Ping Xie, Wulin Yang, Lei Zhang & Hong-Qiang Wang. (2022)
Identifying Biomarkers of Cisplatin Sensitivity in Non-Small Cell Lung
Cancer
via
Comprehensive Integrative Analysis
. Current Bioinformatics 17:6, pages 498-509.
Crossref
Crossref
Meghan Grojean, Margaret A. Schwarz, Johann R. Schwarz, Sazzad Hassan, Urz von Holzen, Changhua Zhang, Roderich E. Schwarz & Niranjan Awasthi. (2021) Targeted dual inhibition of c‐Met/VEGFR2 signalling by foretinib improves antitumour effects of nanoparticle paclitaxel in gastric cancer models. Journal of Cellular and Molecular Medicine 25:11, pages 4950-4961.
Crossref
Crossref
Shao-Long Chen, Guo-Ping Wang, Dan-Rong Shi, Shu-Hao Yao, Ke-Da Chen & Hang-Ping Yao. (2021) RON in hepatobiliary and pancreatic cancers: Pathogenesis and potential therapeutic targets. World Journal of Gastroenterology 27:20, pages 2507-2520.
Crossref
Crossref
Seokhwi Kim, Ji Mi Ahn, Won Jung Bae, Jae Ho Han & Dakeun Lee. (2020) Quantitation of ligand is critical for ligand-dependent MET signalling activation and determines MET-targeted therapeutic response in gastric cancer. Gastric Cancer 24:3, pages 577-588.
Crossref
Crossref
Ya’nan Yang, Chenchen Wang, Congqi Dai, Xinyang Liu, Wenhua Li, Mingzhu Huang, Xiaoying Zhao, Dongmei Ji, Jin Li & Weijian Guo. (2021) Amplification and expression of c-MET correlate with poor prognosis of patients with gastric cancer and upregulate the expression of PDL1. Acta Biochimica et Biophysica Sinica 53:5, pages 547-557.
Crossref
Crossref
Mijuan Shi, Hongrui Luo, Wanting Zhang, Yinjun Jiang, Ji Chen, Yingyin Cheng, Wei Hu & Xiao-Qin Xia. (2021) A genome-wide linkage map and QTL mapping for growth traits of Asian rice-field eel (Monopterus albus). Aquaculture 536, pages 736394.
Crossref
Crossref
Ju-Yoon Yoon, Julia Y. Wang & Michael H.A. Roehrl. (2020) A combined FAK, c-MET, and MST1R three-protein panel risk-stratifies colorectal cancer patients. Translational Oncology 13:11, pages 100836.
Crossref
Crossref
Alireza Tabibzadeh, Fahimeh Safarnezhad Tameshkel, Yousef Moradi, Saber Soltani, Maziar Moradi-Lakeh, G. Hossein Ashrafi, Nima Motamed, Farhad Zamani, Seyed Abbas Motevalian, Mahshid Panahi, Maryam Esghaei, Hossein Ajdarkosh, Alireza Mousavi-Jarrahi & Mohammad Hadi Karbalaie Niya. (2020) Signal transduction pathway mutations in gastrointestinal (GI) cancers: a systematic review and meta-analysis. Scientific Reports 10:1.
Crossref
Crossref
Lynn K.H. Tran, Paul M.H. Tran, David P. Mysona, Sharad B. Purohit, Emily Myers, Won Sok Lee, Boying Dun, Duo Xu, Haitao Liu, Diane Hopkins, John Nechtman, Chris L. Scelsi, Pardeep K. Mittal, Daniel Kleven, John J. Wallbillich, Bunja Rungruang, Sharad Ghamande & Jin-Xiong She. (2020) A 73-gene proliferative transcriptomic signature predicts uterine serous carcinoma patient survival and response to primary therapy. Gynecologic Oncology 157:2, pages 340-347.
Crossref
Crossref
Hang-Ping Yao, Sreedhar Reddy Suthe, Xiang-Min Tong & Ming-Hai Wang. (2020) Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody–drug conjugates as lead drug candidates for clinical trials. Therapeutic Advances in Medical Oncology 12, pages 175883592092006.
Crossref
Crossref
Xin Yu Koh, Xiao Hui Koh, Le-ann Hwang, Fernando Jose Ferrer, Siti Aishah Binte Rahmat, Dilraj Lama & David P. Lane. (2019) Therapeutic anti-cancer activity of antibodies targeting sulfhydryl bond constrained epitopes on unglycosylated RON receptor tyrosine kinase. Oncogene 38:48, pages 7342-7356.
Crossref
Crossref
Sun‑Ae Kim, Kyung‑Hwa Lee, Dong Hoon Lee, Joon Kyoo Lee, Sang Chul Lim, Young‑Eun Joo, Ik‑Joo Chung, Myung‑Giun Noh & Tae Mi Yoon. (2019) Receptor tyrosine kinase, RON, promotes tumor progression by regulating EMT and the MAPK signaling pathway in human oral squamous cell carcinoma. International Journal of Oncology.
Crossref
Crossref
Stefan Mereiter, Álvaro M. Martins, Catarina Gomes, Meritxell Balmaña, Joana A. Macedo, Karol Polom, Franco Roviello, Ana Magalhães & Celso A. Reis. (2019)
O‐glycan truncation enhances cancer‐related functions of
CD
44 in gastric cancer
. FEBS Letters 593:13, pages 1675-1689.
Crossref
Crossref
Donghui Zhou, Ling Huang, Yong Zhou, Tao Wei, Lina Yang & Chao Li. (2019) RON and RONΔ160 promote gastric cancer cell proliferation, migration, and adaption to hypoxia via interaction with β-catenin. Aging 11:9, pages 2735-2748.
Crossref
Crossref
Anne-Marie Baird, David Easty, Monika Jarzabek, Liam Shiels, Alex Soltermann, Sonja Klebe, Stéphane Raeppel, Lauren MacDonagh, Chengguang Wu, Kim Griggs, Michaela B. Kirschner, Bryan Stanfill, Daisuke Nonaka, Chandra M. Goparaju, Bruno Murer, Dean A. Fennell, Dearbhaile M. O'Donnell, Martin P. Barr, Luciano Mutti, Glen Reid, Stephen Finn, Sinead Cuffe, Harvey I. Pass, Isabelle Opitz, Annette T. Byrne, Kenneth J. O'Byrne & Steven G. Gray. (2019) When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?. Frontiers in Endocrinology 10.
Crossref
Crossref
Qianyu Guo, Fan Huang, Christophe Goncalves, Sonia V. del Rincón & Wilson H. MillerJrJr. 2019. Immunotherapy of Cancer. Immunotherapy of Cancer
1
62
.
Najme Faham, Ling Zhao & Alana L. Welm. (2018) mTORC1 is a key mediator of RON-dependent breast cancer metastasis with therapeutic potential. npj Breast Cancer 4:1.
Crossref
Crossref
Mark Wortinger, Jonathan Tetreault, Nick Loizos & Ling Liu. 2018. Extracellular Targeting of Cell Signaling in Cancer. Extracellular Targeting of Cell Signaling in Cancer
199
227
.
Silvia Benvenuti, Melissa Milan & Paolo M. Comoglio. 2018. Extracellular Targeting of Cell Signaling in Cancer. Extracellular Targeting of Cell Signaling in Cancer
1
43
.
Steven B. Maron, Lindsay Alpert, Heewon A. Kwak, Samantha Lomnicki, Leah Chase, David Xu, Emily O'Day, Rebecca J. Nagy, Richard B. Lanman, Fabiola Cecchi, Todd Hembrough, Alexa Schrock, John Hart, Shu-Yuan Xiao, Namrata Setia & Daniel V.T. Catenacci. (2018)
Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for
EGFR
-Amplified Gastroesophageal Adenocarcinoma
. Cancer Discovery 8:6, pages 696-713.
Crossref
Crossref
Melissa Milan, Silvia Benvenuti, Alice Maria Balderacchi, Anna Rita Virzì, Alessandra Gentile, Rebecca Senetta, Paola Cassoni, Paolo Maria Comoglio & Giulia Maria Stella. (2018) RON tyrosine kinase mutations in brain metastases from lung cancer. ERJ Open Research 4:1, pages 00083-2017.
Crossref
Crossref
Daniel V T Catenacci, Niall C Tebbutt, Irina Davidenko, André M Murad, Salah-Eddin Al-Batran, David H Ilson, Sergei Tjulandin, Evengy Gotovkin, Boguslawa Karaszewska, Igor Bondarenko, Mohamedtaki A Tejani, Anghel A Udrea, Mustapha Tehfe, Ferdinando De Vita, Cheryl Turkington, Rui Tang, Agnes Ang, Yilong Zhang, Tien Hoang, Roger Sidhu & David Cunningham. (2017) Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology 18:11, pages 1467-1482.
Crossref
Crossref
Steven B. Maron & Daniel V.T. Catenacci. (2017) Update on Gastroesophageal Adenocarcinoma Targeted Therapies. Hematology/Oncology Clinics of North America 31:3, pages 511-527.
Crossref
Crossref
Xu Zhang, Tapan Maity, Manoj K. Kashyap, Mukesh Bansal, Abhilash Venugopalan, Sahib Singh, Shivangi Awasthi, Arivusudar Marimuthu, Harrys Kishore Charles Jacob, Natalya Belkina, Stephanie Pitts, Constance M. Cultraro, Shaojian Gao, Guldal Kirkali, Romi Biswas, Raghothama Chaerkady, Andrea Califano, Akhilesh Pandey & Udayan Guha. (2017) Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response. Molecular & Cellular Proteomics 16:5, pages 891-910.
Crossref
Crossref
Steven B. Maron & Daniel V.T. Catenacci. (2017) Novel Targeted Therapies for Esophagogastric Cancer. Surgical Oncology Clinics of North America 26:2, pages 293-312.
Crossref
Crossref
Daniel V. T. Catenacci, Agnes Ang, Wei‐Li Liao, Jing Shen, Emily O'Day, Robert D. Loberg, Fabiola Cecchi, Todd Hembrough, Annamaria Ruzzo & Francesco Graziano. (2016) MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma. Cancer 123:6, pages 1061-1070.
Crossref
Crossref
Akanksha Baharani, Brett Trost, Anthony Kusalik & Scott Napper. (2017) Technological advances for interrogating the human kinome. Biochemical Society Transactions 45:1, pages 65-77.
Crossref
Crossref
Jun-Feng Chen, Bi-Xia Yu, Rui Yu, Liang Ma, Xiu-Yi Lv, Yue Cheng & Qi Ma. (2017) Monoclonal antibody Zt/g4 targeting RON receptor tyrosine kinase enhances chemosensitivity of bladder cancer cells to Epirubicin by promoting G1/S arrest and apoptosis. Oncology Reports.
Crossref
Crossref
Sung Yeul YangThi Thinh NguyenTrong Thuan UngYoung Do Jung. (2017) Role of Recepteur D'origine Nantais on Gastric Cancer Development and Progression. Chonnam Medical Journal 53:3, pages 178.
Crossref
Crossref
Omid Zarei, Silvia Benvenuti, Fulya Ustun-Alkan, Maryam Hamzeh-Mivehroud & Siavoush Dastmalchi. (2016) Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery. Journal of Cancer Research and Clinical Oncology 142:12, pages 2429-2446.
Crossref
Crossref
Daniel V. T. Catenacci, Wei-Li Liao, Lei Zhao, Emma Whitcomb, Les Henderson, Emily O’Day, Peng Xu, Sheeno Thyparambil, David Krizman, Kathleen Bengali, Jamar Uzzell, Marlene Darfler, Fabiola Cecchi, Adele Blackler, Yung-Jue Bang, John Hart, Shu-Yuan Xiao, Sang Mee Lee, Jon Burrows & Todd Hembrough. (2015) Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH. Gastric Cancer 19:4, pages 1066-1079.
Crossref
Crossref
Stefan Mereiter, Ana Magalhães, Barbara Adamczyk, Chunsheng Jin, Andreia Almeida, Lylia Drici, Maria Ibáñez-Vea, Catarina Gomes, José A. Ferreira, Luis P. Afonso, Lúcio L. Santos, Martin R. Larsen, Daniel Kolarich, Niclas G. Karlsson & Celso A. Reis. (2016) Glycomic analysis of gastric carcinoma cells discloses glycans as modulators of RON receptor tyrosine kinase activation in cancer. Biochimica et Biophysica Acta (BBA) - General Subjects 1860:8, pages 1795-1808.
Crossref
Crossref
J Chakedis, R French, M Babicky, D Jaquish, H Howard, E Mose, R Lam, P Holman, J Miyamoto, Z Walterscheid & A M Lowy. (2015) A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells. Oncogene 35:25, pages 3249-3259.
Crossref
Crossref
Stefan Mereiter, Meritxell Balmaña, Joana Gomes, Ana Magalhães & Celso A. Reis. (2016) Glycomic Approaches for the Discovery of Targets in Gastrointestinal Cancer. Frontiers in Oncology 6.
Crossref
Crossref
Jung-Soo PyoGuhyun KangHyunjin Cho. (2016) Clinicopathological Significance and Diagnostic Accuracy of c-MET Expression by Immunohistochemistry in Gastric Cancer: A Meta-Analysis. Journal of Gastric Cancer 16:3, pages 141.
Crossref
Crossref
Marie‐Luise Metzger, Hans‐Michael Behrens, Christine Böger, Jochen Haag, Sandra Krüger & Christoph Röcken. (2015) MET in gastric cancer – discarding a 10% cutoff rule. Histopathology 68:2, pages 241-253.
Crossref
Crossref
Najme Faham & Alana L. Welm. (2016) RON Signaling Is a Key Mediator of Tumor Progression in Many Human Cancers. Cold Spring Harbor Symposia on Quantitative Biology 81, pages 177-188.
Crossref
Crossref
Zheng Wu, Zhe Zhang, Xiaoxiao Ge, Ying Lin, Congqi Dai, Jinjia Chang, Xinyang Liu, Ruixuan Geng, Chenchen Wang, Huan Chen, Menghong Sun, Weijian Guo & Jin Li. (2015) Identification of short-form RON as a novel intrinsic resistance mechanism for anti-MET therapy in MET-positive gastric cancer. Oncotarget 6:38, pages 40519-40534.
Crossref
Crossref
Izhar Singh Batth, Huiyoung Yun & Addankl P. Kumar. (2015) Recepteur d'origine nantais (RON), more than a kinase: Role in castrate-resistant prostate cancer. Molecular Carcinogenesis 54:10, pages 937-946.
Crossref
Crossref
Ismael Riquelme, Kathleen Saavedra, Jaime A. Espinoza, Helga Weber, Patricia García, Bruno Nervi, Marcelo Garrido, Alejandro H. Corvalán, Juan Carlos Roa & Carolina Bizama. (2015) Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy. Oncotarget 6:28, pages 24750-24779.
Crossref
Crossref
Hiroyuki Watanabe, Yukihiro Yokoyama, Toshio Kokuryo, Tomoki Ebata, Tsuyoshi Igami, Gen Sugawara, Takashi Mizuno, Yoshie Shimoyama & Masato Nagino. (2015) Prognostic Value of Hepatocyte Growth Factor Receptor Expression in Patients with Perihilar Cholangiocarcinoma. Annals of Surgical Oncology 22:7, pages 2235-2242.
Crossref
Crossref
Young Wha Koh, Yang-Soon Park, Hyo Jeong Kang, Ju Hyun Shim & Eunsil Yu. (2015) MET is a predictive factor for late recurrence but not for overall survival of early stage hepatocellular carcinoma. Tumor Biology 36:7, pages 4993-5000.
Crossref
Crossref
Daniel V.T. Catenacci. (2015) Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity. Molecular Oncology 9:5, pages 967-996.
Crossref
Crossref
Eiichiro Noguchi, Noboru Saito, Makio Kobayashi & Shingo Kameoka. (2015) Clinical significance of hepatocyte growth factor/c-Met expression in the assessment of gastric cancer progression. Molecular Medicine Reports.
Crossref
Crossref
Dong-Hui Zhou, Chao Li & Li-Na Yang. (2015) Variant RONΔ160 of the RON receptor tyrosine kinase promotes the growth and invasion in vitro and in vivo in gastric cancer cell lines. Cancer Cell International 15:1, pages 9.
Crossref
Crossref
Ling Liu, Wei Zeng, Mark A. Wortinger, S. Betty Yan, Paul Cornwell, Victoria L. Peek, Jennifer R. Stephens, Jonathan W. Tetreault, Jinqi Xia, Jason R. Manro, Kelly M. Credille, Darryl W. Ballard, Patricia Brown-Augsburger, Volker Wacheck, Chi-Kin Chow, Lihua Huang, Yong Wang, Irene Denning, Julian Davies, Ying Tang, Peter Vaillancourt & Jirong Lu. (2014) LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth. Clinical Cancer Research 20:23, pages 6059-6070.
Crossref
Crossref
Zhenfu Han, Peter K. W. Harris, Darin E. Jones, Ryan Chugani, Tommy Kim, Manjula Agarwal, Wei Shen, Scott A. Wildman & James W. Janetka. (2014) Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer. ACS Medicinal Chemistry Letters 5:11, pages 1219-1224.
Crossref
Crossref
F Graziano, V Catalano, P Lorenzini, E Giacomini, D Sarti, G Fiorentini, M De Nictolis, M Magnani & A Ruzzo. (2014) Clinical impact of the HGF/MET pathway activation in patients with advanced gastric cancer treated with palliative chemotherapy. The Pharmacogenomics Journal 14:5, pages 418-423.
Crossref
Crossref
Young Wha Koh, Hee Jin Lee, Jin-Hee Ahn, Jong Won Lee & Gyungyub Gong. (2014) MET expression is associated with disease-specific survival in breast cancer patients in the neoadjuvant setting. Pathology - Research and Practice 210:8, pages 494-500.
Crossref
Crossref
Daniel V. T. Catenacci, Wei-Li Liao, Sheeno Thyparambil, Les Henderson, Peng Xu, Lei Zhao, Brittany Rambo, John Hart, Shu-Yuan Xiao, Kathleen Bengali, Jamar Uzzell, Marlene Darfler, David B. Krizman, Fabiola Cecchi, Donald P. Bottaro, Theodore Karrison, Timothy D. Veenstra, Todd Hembrough & Jon Burrows. (2014) Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue. PLoS ONE 9:7, pages e100586.
Crossref
Crossref
Stephen P. Hack, Jean-Marie Bruey & Hartmut Koeppen. (2014) HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development. Oncotarget 5:10, pages 2866-2880.
Crossref
Crossref
Ravi Salgia, Premal Patel, John Bothos, Wei Yu, Steve Eppler, Priti Hegde, Shuang Bai, Surinder Kaur, Ihsan Nijem, Daniel V.T. Catenacci, Amy Peterson, Mark J. Ratain, Blase Polite, Janice M. Mehnert & Rebecca A. Moss. (2014) Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies. Clinical Cancer Research 20:6, pages 1666-1675.
Crossref
Crossref
Ichiro Kawada, Rifat Hasina, Qudsia Arif, Jeffrey Mueller, Erin Smithberger, Aliya N. Husain, Everett E. Vokes & Ravi Salgia. (2014) Dramatic Antitumor Effects of the Dual MET/RON Small-Molecule Inhibitor LY2801653 in Non–Small Cell Lung Cancer. Cancer Research 74:3, pages 884-895.
Crossref
Crossref
Zhi Peng, Yan Zhu, Qianqian Wang, Jing Gao, Yilin Li, Yanyan Li, Sai Ge & Lin Shen. (2014) Prognostic Significance of MET Amplification and Expression in Gastric Cancer: A Systematic Review with Meta-Analysis. PLoS ONE 9:1, pages e84502.
Crossref
Crossref
Giuseppe Giaccone & Jean-Charles SoriaApoorva Chawla, Ravi Salgia & Victoria Villaflor. 2013. Targeted Therapies in Oncology, Second Edition. Targeted Therapies in Oncology, Second Edition
191
216
.
Young Wha Koh, Hee Sang Hwang, Se Jin Jung, Chansik Park, Dok Hyun Yoon, Cheolwon Suh & Jooryung Huh. (2013) Receptor tyrosine kinases MET and RON as prognostic factors in diffuse large B-cell lymphoma patients receiving R-CHOP. Cancer Science 104:9, pages 1245-1251.
Crossref
Crossref
Young Wha Koh, Chansik Park, Dok Hyun Yoon, Cheolwon Suh & Jooryung Huh. (2013) MET and MST1R as prognostic factors for classical Hodgkin's lymphoma. Modern Pathology 26:9, pages 1172-1182.
Crossref
Crossref
Elizabeta C. Popa & Manish A. Shah. (2013) Met, IGF1R, and Other New Targets in Upper GI Malignancies. Current Treatment Options in Oncology 14:3, pages 321-336.
Crossref
Crossref
Yi Zou, Gillian M. Howell, Lisa E. Humphrey, Jing Wang & Michael G. Brattain. (2013) Ron Knockdown and Ron Monoclonal Antibody IMC-RON8 Sensitize Pancreatic Cancer to Histone Deacetylase Inhibitors (HDACi). PLoS ONE 8:7, pages e69992.
Crossref
Crossref
Hang-Ping Yao, Yong-Qing Zhou, Ruiwen Zhang & Ming-Hai Wang. (2013) MSP–RON signalling in cancer: pathogenesis and therapeutic potential. Nature Reviews Cancer 13:7, pages 466-481.
Crossref
Crossref
J Keller, A S Nimnual, K R Shroyer, C Joy, I Ischenko, C S Chandler, L M Dong, M J Hayman & E L Chan. (2013) Ron tyrosine kinase receptor synergises with EGFR to confer adverse features in head and neck squamous cell carcinoma. British Journal of Cancer 109:2, pages 482-492.
Crossref
Crossref
Chris Cain. (2013) RON's new role. Science-Business eXchange 6:21.
Crossref
Crossref
Tanguy Seiwert, John Sarantopoulos, Howard Kallender, Stewart McCallum, Harold N. Keer & George BlumenscheinJr.Jr.. (2012) Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Investigational New Drugs 31:2, pages 417-424.
Crossref
Crossref
Manish A. Shah, Zev A. Wainberg, Daniel V. T. Catenacci, Howard S. Hochster, James Ford, Pamela Kunz, Fa-Chyi Lee, Howard Kallender, Fabiola Cecchi, Daniel C. Rabe, Harold Keer, Anne-Marie Martin, Yuan Liu, Robert Gagnon, Peter Bonate, Li Liu, Tona Gilmer & Donald P. Bottaro. (2013) Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. PLoS ONE 8:3, pages e54014.
Crossref
Crossref
Carole M Tactacan, David K Chang, Mark J Cowley, Emily S Humphrey, Jianmin Wu, Anthony J Gill, Angela Chou, Katia Nones, Sean M Grimmond, Robert L Sutherland, Andrew V Biankin & Roger J Daly. (2012) RON is not a prognostic marker for resectable pancreatic cancer. BMC Cancer 12:1.
Crossref
Crossref
Daniel V. T. Catenacci, Les Henderson, Shu-Yuan Xiao, Premal Patel, Robert L. Yauch, Priti Hegde, Jiping Zha, Ajay Pandita, Amy Peterson & Ravi Salgia. (2011) Durable Complete Response of Metastatic Gastric Cancer with Anti-Met Therapy Followed by Resistance at Recurrence. Cancer Discovery 1:7, pages 573-579.
Crossref
Crossref
J. Jean Cui, Michelle Tran-Dubé, Hong Shen, Mitchell Nambu, Pei-Pei Kung, Mason Pairish, Lei Jia, Jerry Meng, Lee Funk, Iriny Botrous, Michele McTigue, Neil Grodsky, Kevin Ryan, Ellen Padrique, Gordon Alton, Sergei Timofeevski, Shinji Yamazaki, Qiuhua Li, Helen Zou, James Christensen, Barbara Mroczkowski, Steve Bender, Robert S. Kania & Martin P. Edwards. (2011) Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK). Journal of Medicinal Chemistry 54:18, pages 6342-6363.
Crossref
Crossref